Analysts Set Prestige Consumer Healthcare Inc. (NYSE:PBH) Price Target at $97.00

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBHGet Free Report) have been given a consensus rating of “Moderate Buy” by the three brokerages that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $97.00.

A number of equities research analysts have issued reports on PBH shares. StockNews.com upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Saturday. BMO Capital Markets cut their price objective on Prestige Consumer Healthcare from $124.00 to $117.00 and set an “outperform” rating for the company in a research report on Wednesday, November 15th. Finally, Royal Bank of Canada cut their price objective on Prestige Consumer Healthcare from $110.00 to $103.00 and set a “sector perform” rating for the company in a research report on Wednesday, November 15th.

Check Out Our Latest Stock Report on PBH

Insider Buying and Selling

In other news, SVP Mary Beth Fritz sold 5,336 shares of the company’s stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $69.00, for a total transaction of $368,184.00. Following the transaction, the senior vice president now directly owns 15,934 shares of the company’s stock, valued at $1,099,446. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 1.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several hedge funds have recently made changes to their positions in PBH. Advisor Group Holdings Inc. boosted its stake in shares of Prestige Consumer Healthcare by 10.9% during the 1st quarter. Advisor Group Holdings Inc. now owns 3,694 shares of the company’s stock worth $196,000 after acquiring an additional 363 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Prestige Consumer Healthcare by 10.8% during the 1st quarter. JPMorgan Chase & Co. now owns 210,242 shares of the company’s stock worth $11,130,000 after acquiring an additional 20,496 shares in the last quarter. Raymond James & Associates boosted its stake in shares of Prestige Consumer Healthcare by 84.8% during the 1st quarter. Raymond James & Associates now owns 9,326 shares of the company’s stock worth $494,000 after acquiring an additional 4,279 shares in the last quarter. US Bancorp DE boosted its stake in shares of Prestige Consumer Healthcare by 67.7% during the 1st quarter. US Bancorp DE now owns 10,237 shares of the company’s stock worth $541,000 after acquiring an additional 4,132 shares in the last quarter. Finally, HighTower Advisors LLC boosted its stake in shares of Prestige Consumer Healthcare by 6.0% during the 1st quarter. HighTower Advisors LLC now owns 5,791 shares of the company’s stock worth $307,000 after acquiring an additional 330 shares in the last quarter. 99.95% of the stock is owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Trading Down 0.9 %

Shares of PBH stock opened at $68.02 on Friday. Prestige Consumer Healthcare has a 12-month low of $55.96 and a 12-month high of $69.29. The company has a quick ratio of 1.92, a current ratio of 3.09 and a debt-to-equity ratio of 0.75. The business has a 50-day moving average price of $61.14 and a two-hundred day moving average price of $60.22. The firm has a market cap of $3.38 billion, a P/E ratio of -41.48, a price-to-earnings-growth ratio of 1.98 and a beta of 0.50.

Prestige Consumer Healthcare (NYSE:PBHGet Free Report) last issued its quarterly earnings results on Thursday, February 8th. The company reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $1.04 by $0.02. The firm had revenue of $282.74 million for the quarter, compared to analysts’ expectations of $280.25 million. Prestige Consumer Healthcare had a positive return on equity of 14.09% and a negative net margin of 7.11%. The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.04 EPS. Equities analysts anticipate that Prestige Consumer Healthcare will post 4.33 EPS for the current fiscal year.

Prestige Consumer Healthcare Company Profile

(Get Free Report

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

Read More

Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.